NCT06709274 - Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC | Biotech Hunter

Enrollment

342

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2032

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib

80mg daily, for EGFR-positive patients

DRUG

Alectinib

600mg BID, for ALK-rearranged patients

DRUG

TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

Toripalimab 240mg + Platinum-based chemotherapy (Q3W for 4 cycles), followed by Toripalimab maintenance therapy (240mg Q3W for one year), for EGFR/ALK wildtype patients

Trial Locations (15)

Unknown

Dongguan People's Hospital, Dongguan

The First People's Hospital of Foshan, Foshan

Guangdong Provincial People's Hostpital, Guangzhou

ZhuJiang Hospital of Southern Medical University, Guangzhou

Peking University Shenzhen Hospital, Shenzhen

Shenzhen People's Hospital, Shenzhen

The Second Affiliated Hospital of Guangxi Medical University, Nanning

Guizhou Provincial People's Hospital, Guiyang

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan

Hunan Cancer Hospital, Changsha

Xiangya Hospital of Central South University, Changsha

Jiangsu Cancer Hospital, Nanjing

Affiliated Hospital of Nantong University, Nantong

Sichuan Provincial People's Hospital, Chengdu

The Third People's Hospital of Chengdu, Chengdu